Rendering

Component: (Network and Table)
Network
2314301 - Disclosure - Equity-Based Compensation (Tables)
(http://www.amagpharma.com/role/EquityBasedCompensationTables)
Table(Implied)
Slicers (applies to each fact value in each table cell)
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]Period [Axis]
2016-01-01 - 2016-12-31
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
 
Summary of details regarding stock options granted under equity incentive plans
The following table summarizes details regarding stock options granted under our equity incentive plans for the year ended December 31, 2016:
 
December 31, 2016
 
Options
 
Weighted Average Exercise Price
 
Weighted Average Remaining Contractual Term
 
Aggregate Intrinsic Value
($ in thousands)
Outstanding at beginning of year
2,904,177

    
$
34.97

    

    
$

Granted
784,048

 
24.59

 

 

Exercised
(155,705
)
 
17.99

 

 

Expired and/or forfeited
(419,342
)
 
44.10

 

 

Outstanding at end of year
3,113,178

 
$
31.97

 
7.4

 
$
28,113

Outstanding at end of year - vested and unvested expected to vest
2,915,930

 
$
31.53

 
7.4

 
$
27,038

Exercisable at end of year
1,536,405

 
$
27.92

 
6.3

 
$
17,928

The following table summarizes stock option activity during 2016:
 
2007 Equity
 
2000 Equity
 
2013 Lumara
 
Inducement
 
 
 
Plan
 
Plan
 
Equity Plan
 
Grants
 
Total
Outstanding at December 31, 2015
1,963,162

 
14,040

 
96,000

 
830,975

 
2,904,177

Granted
581,648

 

 
92,400

 
110,000

 
784,048

Exercised
(134,455
)
 

 

 
(21,250
)
 
(155,705
)
Expired or terminated
(251,533
)
 
(8,840
)
 
(54,219
)
 
(104,750
)
 
(419,342
)
Outstanding at December 31, 2016
2,158,822

 
5,200

 
134,181

 
814,975

 
3,113,178

 
 
Summary of details regarding restricted stock units granted under equity incentive plans
The following table summarizes RSU activity during 2016:
 
2007 Equity
 
2000 Equity
 
2013 Lumara
 
Inducement
 
 
 
Plan
 
Plan
 
Equity Plan
 
Grants
 
Total
Outstanding at December 31, 2015
446,330

 

 
52,350

 
155,675

 
654,355

Granted
659,618

 

 
1,500

 
64,500

 
725,618

Vested
(209,599
)
 

 
(16,749
)
 
(74,219
)
 
(300,567
)
Expired or terminated
(122,545
)
 

 
(9,407
)
 
(10,500
)
 
(142,452
)
Outstanding at December 31, 2016
773,804

 

 
27,694

 
135,456

 
936,954

The following table summarizes details regarding RSUs granted under our equity incentive plans for the year ended December 31, 2016:
 
December 31, 2016
 
Restricted Stock Units
 
Weighted Average Grant Date Fair Value
Outstanding at beginning of year
654,355

    
$
36.90

Granted
725,618

 
22.28

Vested
(300,567
)
 
30.38

Forfeited
(142,452
)
 
26.66

Outstanding at end of year
936,954

 
$
28.78

Outstanding at end of year and expected to vest
781,165

 
$
28.79

 
 
Schedule of equity-based compensation expense
Equity-based compensation expense for 2016, 2015 and 2014 consisted of the following (in thousands):
 
Years Ended December 31,
 
2016
 
2015
 
2014
Cost of product sales and services
$
520

 
$
371

 
$
122

Research and development
3,476

 
2,992

 
1,596

Selling, general and administrative
18,547

 
13,874

 
6,907

Total equity-based compensation expense
$
22,543

 
$
17,237

 
$
8,625

Income tax effect
(6,232
)
 
(4,885
)
 

After-tax effect of equity-based compensation expense
$
16,311

 
$
12,352

 
$
8,625

 
 
Schedule of share-based payment award, stock options, valuation assumptions
The following table summarizes the weighted average assumptions we utilized for purposes of valuing grants of options to our employees and non-employee directors:
 
Years Ended December 31,
 
2016
 
2015
 
2014
 
 
 
Non-Employee
 
 
 
Non-Employee
 
 
 
Non-Employee
 
Employees
 
Directors
 
Employees
 
Directors
 
Employees
 
Directors
Risk free interest rate (%)
1.32
    
1.10
    
1.55
    
1.24
    
1.56
    
1.28
Expected volatility (%)
49
 
54
 
47
 
46
 
47
 
46
Expected option term (years)
5.00
 
3.00
 
5.00
 
4.00
 
5.00
 
4.00
Dividend yield
none
 
none
 
none
 
none
 
none
 
none